Sanofi India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on May 15, 2025. Further, the company has informed the Exchange regarding voting results.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India submitted the scrutinizer's report for its 69th AGM held on May 15, 2025 via video conferencing, along with consolidated voting results. All 8 resolutions were passed with overwhelming majority — approval ranged from 99.71% to 99.99% across items. Key approvals include adoption of audited financial statements for FY ended December 31, 2024, declaration of a final dividend of Rs. 117 per equity share (face value Rs. 10), re-appointment of directors Ms. Renee Amonkar and Mr. Rachid Ayari (retirement by rotation), re-appointment of Mr. Rahul Bhatnagar as Independent Director for a second five-year term (July 2025 to July 2030), re-designation of Mr. Rodolfo Hrosz as Non-Executive Director, appointment of M/s. Parikh & Associates as Secretarial Auditor for FY 2025-2029, and ratification of Cost Auditor remuneration for FY 2025. On the cut-off date of May 8, 2025, the company had 69,842 members holding 2,30,30,622 shares, with 76 members present at the AGM. No invalid votes were recorded on any resolution.
Shareholders can expect the Rs. 117 per share final dividend to be disbursed in due course. The near-unanimous approval on all resolutions, including board re-appointments and auditor ratification, signals strong shareholder confidence with no contentious issues raised.